Want to see COCH full AI Analyst Report?
COCH Stock Chart & Stats
$0.66
>-$0.01(-1.13%)
At close: 4:00 PM EDT
$0.66
>-$0.01(-1.13%)
Day’s Range― - ―
52-Week Range$0.36 - $1.89
Previous CloseN/A
Volume100.00
Average Volume (3M)394.38K
Market Cap
$57.04M
Enterprise Value$63.53
Total Cash (Recent Filing)$19.68M
Total Debt (Recent Filing)$810.00K
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Nov 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding77,194,595
10 Day Avg. Volume193,663
30 Day Avg. Volume394,378
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-1.31
Price to Sales (P/S)63.80
P/FCF Ratio-0.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.25Price Target Upside240.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$200.00K
Bulls Say, Bears Say
Bulls Say
Low Reported LeverageThe latest balance sheet shows limited reported debt relative to equity, reducing immediate interest and refinancing pressure. This provides some financial flexibility while Envoy advances development, although historical equity volatility limits confidence.
Differentiated Implant TechnologyA fully implanted design could differentiate Envoy from conventional hearing aids and external cochlear implants by improving usability, convenience and patient compliance. If clinically and commercially validated, this may support a durable niche in hearing health.
Reduced Planned Equity DilutionEnding the ATM facility removes an available mechanism for routine share issuance and may limit near-term dilution while preserving the existing ownership base. It also indicates management believes current resources can support portfolio advancement for now.
Bears Say
Minimal And Declining RevenueVery low, declining revenue shows that commercialization has not yet reached meaningful scale. Negative gross profit indicates current sales do not cover direct costs, limiting operating leverage and making sustained profitability dependent on successful adoption.
Severe Cash BurnPersistent operating and free-cash-flow deficits mean Envoy is not self-funding research, development or operations. Continued dependence on external capital could constrain execution and create future dilution or financing risk if commercialization remains slow.
Nasdaq Listing And Dilution RiskFailure to restore the minimum bid price creates an ongoing listing risk and may force a reverse split or other corporate action. Such measures can complicate investor access, increase uncertainty and add to the company’s broader capitalization risk.
Envoy Medical News
COCH FAQ
What was Envoy Medical’s price range in the past 12 months?
Envoy Medical lowest stock price was $0.36 and its highest was $1.89 in the past 12 months.
What is Envoy Medical’s market cap?
Envoy Medical’s market cap is $57.04M.
When is Envoy Medical’s upcoming earnings report date?
Envoy Medical’s upcoming earnings report date is Nov 18, 2026 which is in 90 days.
How were Envoy Medical’s earnings last quarter?
Envoy Medical released its earnings results on Aug 10, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.01.
Is Envoy Medical overvalued?
According to Wall Street analysts Envoy Medical’s price is currently Undervalued.
Does Envoy Medical pay dividends?
Envoy Medical does not currently pay dividends.
What is Envoy Medical’s EPS estimate?
Envoy Medical’s EPS estimate is -0.07.
How many shares outstanding does Envoy Medical have?
Envoy Medical has 77,194,595 shares outstanding.
What happened to Envoy Medical’s price movement after its last earnings report?
Envoy Medical reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went up 5.067%.
Which hedge fund is a major shareholder of Envoy Medical?
Currently, no hedge funds are holding shares in COCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Envoy Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.25 (240.91% Upside)
$2.25 (240.91% Upside)
Hedge Fund Trend
Decreased
By 297.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
141.91%
Trailing 12-Months
Company Description
Envoy Medical
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.
COCH Stock 12 Month Forecast
Average Price Target
$2.25
▲(240.91% Upside)
Technical Analysis
Xtant Medical Holdings
―
Inspire Medical Systems
―
Neuronetics
―
NeuroOne Medical Technologies
―
NeuroPace
―
Ownership Overview
40.34% Insiders
1.26% Mutual Funds
19.14% Other Institutional Investors
38.12% Public Companies and
Individual Investors